Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 7, 2011, Pages 1117-1122

  Xu, Zhen Ye ^a   Jin, Chang Juan ^b   Zhou, Cai Cun ^c   Wang, Zhong Qi ^a   Zhou, Wei Dong ^a   Deng, Hai Bin ^a   Zhang, Ming ^a   Su, Wan ^a   Cai, Xiao Yue ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

Advanced non small cell lung cancer; Chemotherapy; Chinese herbal medicine

Indexed keywords

CISPLATIN; FEIYANNING; GEFITINIB; HERBACEOUS AGENT; KANGLIUZENGXIAO; NAVELBINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTRAGALUS MONGHOLICUS; ASTRAGALUS PLANT; ATRACTYLODES; ATRACTYLODES CHINENSIS; ATRACTYLODES MACROCEPHALAE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; COPTIS; COPTIS CHINENSIS; CORNUS; CORNUS OFFICINALIS; DRUG EFFICACY; DRUG WITHDRAWAL; EPIMEDIUM; EPIMEDIUM DAVIDII; FEMALE; GANODERMA LUCIDUM; GASTROINTESTINAL TOXICITY; GYNOSTEMMA PENTAPHYLLUM; HERBAL MEDICINE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE; LIGUSTRUM; LIGUSTRUM LUCIDUM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; PARIS POLYPHYLLA; POLYGONATUM; POLYGONATUM SIBIRICUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOBULBUS CREMASTRAE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE; TOAD; UREA NITROGEN BLOOD LEVEL;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CISPLATIN; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 79959746724     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-0975-3     Document Type: Article

References (30)

1. Anthony HM (1993) Some methodological problems in the assessment of complementary therapy. In: Lewith GT, Aldridge D (eds) Clinical research methodology for complementary therapies. Hodder & Stoughton, London, pp 108-121
2. Antman K, Benson MC, Chabot J et al (2001) Complementary and alternative medicine: the role of the cancer center. J Clin Oncol 19(Suppl):55-60
3. Bensoussan A (1993) Contemporary acupuncture research. Am J Acupunct 19:357-366
4. Bensoussan A, Myers SP (1996) Towards a safer choice: the practice of traditional Chinese medicine in Australia. University of Western Sydney Macarthur, Sydney
5. Blackhall FH, O'brien M, Schmid P et al (2010) A Phase I Study of Vandetanib in combination with Vinorelbine/Cisplatin or Gemcitabine/ Cisplatin as Wrst-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 5(8):1285-1288
6. Favaretto AG (2006) Non-platinum combination of gemcitabine in NSCLC. Ann Oncol 17(Suppl):82-85
7. Gervais R, Ducolone A, Breton JL et al (2005) Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-smallcell lung cancer (NSCLC). Ann Oncol 16:90-96 (Pubitemid 40124484)
8. Giorgio S (2007) Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J Thorac Oncol Suppl 2:S86-S91
9. Guo CY, Yu JC, An ZJ et al (2010) NP and GP regimen as original chemotherapy for advanced non-small cell lung cancer. Chin J Cancer Prev Treat 17(9):703-705
10. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30 (Pubitemid 40310185)
11. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
12. Li XQ, Li J, Shi SB et al (2009) Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 24(4):230-237
13. Martin S, Ulrich C, Munsell M et al (2007) Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist 12:816-824 (Pubitemid 47328225)
14. Martins R, Kelly K, Socinski MA et al (2006) Management of metastatic non-small cell lung cancer in 2006: innovations and unique clinical scenarios. In: Govindan R, Perry MC, Slowinski FH (eds) American Society of Clinical Oncology 2006 Educational Book. American Society of Clinical Oncology, Alexandria, pp 418-423
15. Ng TP, Tan CH, Kua EH (2004) The use of Chinese herbal medicines and their correlates in Chinese older adults: the Singapore Chinese Longitudinal Aging Study. Age Ageing 33:135-142 (Pubitemid 38313111)
16. Pan JH, Han JX, Wu JM et al (2008) MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75(4):380-385
17. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
18. Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27(34):5808-5815
19. Scagliotti GV, Novello S (2006) Current status of adjuvant chemotherapy in NSCLC. Ann Oncol Suppl 5:62-63
20. Sève P, Lai R, Ding K et al (2007) Class III beta-tubulin expression and beneWt from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13(3):994-999 (Pubitemid 46340378)
21. Shibuya K, Mathers CD, Boschi-Pinto C et al (2002) Global, regional estimates of cancer mortality, incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2:37
22. Sparber A, Wootton JC (2001) Surveys of complementary and alternative medicine: part II. Use of alternative and complementary cancer therapies. J Altern Complement Med 7:281-287 (Pubitemid 32574902)
23. Szilasi M, Müller V, Juhász E et al (2009) Cisplatin-vinorelbine chemotherapy in non-small cell lung cancer is safe and well tolerated: results of a retrospective Hungarian clinical data analysis. Expert Opin Drug Saf 8(1):9-14
24. Thatcher N, Chang A, Parikh P et al (2005) GeWtinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527-1537 (Pubitemid 41540110)
25. Vera H, Pierre D, Burton MN, James RR et al (2007) Oral versus intravenous administration of vinorelbine as a single agent for the Wrst-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): a randomized phase II trial. Am J Clin Oncol 30(3):245-251
26. Xue YB, Zhou XY, Zhang YJ (2009) Clinical observation of gemcitabine and cisplatine in the treatment of advanced non-small cell lung cancer. Chin J Clin Oncol Rehabil 16(4):336-337
27. Yoney A, Kandemir O, Akboru H et al (2004) Neoadjuvant paclitaxel, carboplatin, concurrent weekly paclitaxel, conventional radiotherapy for locally advanced NSCLC: 7361. J Clin Oncol 22(Suppl 14):706s
28. Zhao XZ, Xu ZY, Wu ZH (2008) Regulatory eVects of Feiyanning Decoction on pithelial-mesenchymal transition factors Twist, Snail, Sip 1, and E-cadherin. Tumor 28(1):29-31
29. Zhi XY (2009) Epidemiological analysis of lung cancer in China. Zhongguo Chu Fang Yao 83(2):56-57
30. Zhou DH, Lin LZ, Zhou YQ et al (2005) Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional Chinese medicine. Ai Zheng 24(10):1252-1256